selected publications
-
First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Comment
GET IT
Times cited: 15 -
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Molecular therapy : the journal of the American Society of Gene Therapy.
2018
Academic Article
GET IT
Times cited: 52 -
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.
Bone marrow transplantation.
2018
Academic Article
GET IT
Times cited: 6 -
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Leukemia & lymphoma.
2017
Letter
GET IT
Times cited: 6 - Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission. Leukemia & lymphoma. 2017 Comment GET IT
-
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
Blood.
2017
Letter
GET IT
Times cited: 59 -
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Cytotherapy.
2016
Review
GET IT
Times cited: 74 -
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Blood.
2016
Review
GET IT
Times cited: 286